These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2572256)

  • 21. Xamoterol in mild to moderate heart failure: a subgroup analysis of patients with cardiomegaly but no concomitant angina pectoris.
    European 'Corwin' Study Group
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):67S-69S. PubMed ID: 2572258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Assessment of chronotropic effect and arrhythmogenesis on beta 1-partial agonist (Xamoterol) in chronic heart failure].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    Kokyu To Junkan; 1988 Nov; 36(11):1227-33. PubMed ID: 2907820
    [No Abstract]   [Full Text] [Related]  

  • 23. Xamoterol versus digoxin in heart failure.
    Lancet; 1988 Apr; 1(8590):877. PubMed ID: 2895376
    [No Abstract]   [Full Text] [Related]  

  • 24. Lack of tolerance development after long-term administration of the partial beta-adrenoceptor agonist xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Cardiology; 1990; 77(1):30-9. PubMed ID: 1972349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.
    Lancet; 1990 Jul; 336(8706):1-6. PubMed ID: 1694945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ischaemic left ventricular failure: evidence of sustained benefit after 18 months' treatment with xamoterol.
    Vigholt-Sørensen E; Faergeman O
    Br Heart J; 1990 Sep; 64(3):186-9. PubMed ID: 1976339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure.
    Francis GS
    Am Heart J; 1989 Sep; 118(3):642-8. PubMed ID: 2570521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exercise capacity, arrhythmias, humoral and chemical parameters during long-term therapy with xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Int J Cardiol; 1990 Aug; 28(2):197-208. PubMed ID: 1697569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group.
    Lancet; 1988 Mar; 1(8584):489-93. PubMed ID: 2893916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of xamoterol, a beta 1 adrenoceptor partial agonist, in patients with ischaemic dysfunction of the left ventricle.
    Vigholt-Sørensen E; Faergeman O; Snow HM
    Br Heart J; 1989 Nov; 62(5):335-41. PubMed ID: 2574049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of left ventricular contractility and relaxation with the beta 1-adrenergic receptor partial agonist xamoterol at rest and during exercise in patients with postinfarction left ventricular dysfunction. A placebo-controlled randomized trial.
    de Feyter PJ; Serruys PW; Suryapranata H
    Circulation; 1990 Feb; 81(2 Suppl):III99-106. PubMed ID: 1967562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy of xamoterol, a beta 1-adrenoceptor partial agonist, in mild to moderate heart failure. U.K. Xamoterol Study Group.
    Waller DG; Webster J; Sykes CA; Bhalla KK; Wray R
    Eur Heart J; 1989 Nov; 10(11):1003-10. PubMed ID: 2574108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Xamoterol monotherapy in heart failure. The European 'Corwin' Group.
    Timewell RM; Stark RD; Marlow HF
    Eur Heart J; 1990 Apr; 11 Suppl A():62-4. PubMed ID: 1971596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cardiac insufficiency. Current treatment].
    Aumont MC; Castaigne A
    Rev Prat; 1988 Feb; 38(5 Suppl):5-11. PubMed ID: 2895497
    [No Abstract]   [Full Text] [Related]  

  • 35. The effects of the partial beta 1-agonist xamoterol on heart rate and ventricular arrhythmias in patients with mild to moderate heart failure.
    Virk SJ; Anfilogoff NH; Lawson N; Qiang F; Murray RG; Littler WA; Davies MK
    Eur Heart J; 1990 Oct; 11(10):876-84. PubMed ID: 1979946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
    Furlong R; Brogden RN
    Drugs; 1988 Oct; 36(4):455-74. PubMed ID: 2906865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular effects of ICI 118,587, a new beta-adrenoceptor partial agonist in man.
    Sasayama S; Yokawa S; Akiyama M; Mikawa M; Sakai O
    Jpn Circ J; 1986 Jul; 50(7):636-43. PubMed ID: 2877103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Xamoterol in patients with dilated cardiomyopathy: an increase in beta-receptors in lymphocytes.
    Watanabe K; Hirokawa Y; Shibata A
    J Cardiol; 1988 Dec; 18(4):1015-25. PubMed ID: 2908309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Xamoterol in heart failure.
    von Olshausen K
    Lancet; 1988 May; 1(8595):1162. PubMed ID: 2896976
    [No Abstract]   [Full Text] [Related]  

  • 40. Xamoterol in severe heart failure.
    Ikram H; Crozier IG
    Lancet; 1990 Aug; 336(8713):517-8. PubMed ID: 1975033
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.